Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation

Brief takeaway: A Section 337 investigation involving certain drug products containing C-type natriuretic peptide (CNP) variants had a procedural update to reflect a respondent's corporate name change.

What changed: According to the notice, the Commission determined not to review an initial determination (Order No. 45) by the Chief administrative law judge that granted an unopposed motion to amend the complaint and notice of investigation. The notice states the amendment reflects respondent Ascendis Pharma, Inc.'s corporate name change to Ascendis Pharma, LLC.

Who's affected: The notice names the investigation subject as certain drug products containing C-type natriuretic peptide (CNP) variants, and components thereof. It names Ascendis Pharma, Inc. (now Ascendis Pharma, LLC) as a respondent. No HTS chapters, codes, or countries of origin are specified in the notice.

What to review:
- Review whether your imported products may fall within the described category of drug products containing CNP variants or components thereof.
- Check with trade counsel whether this Section 337 investigation may be relevant to your supply chain or suppliers.
- Confirm with your licensed customs broker whether any exclusion order or other remedy has issued in this investigation, since this notice addresses only a procedural name change.

This is general information, not legal advice and not a compliance determination — confirm specifics with a licensed customs broker or trade counsel.